These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 8947918)
1. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Metzger TG; Paterlini MG; Portoghese PS; Ferguson DM Neurochem Res; 1996 Nov; 21(11):1287-94. PubMed ID: 8947918 [TBL] [Abstract][Full Text] [Related]
2. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867 [TBL] [Abstract][Full Text] [Related]
3. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists. Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076 [TBL] [Abstract][Full Text] [Related]
4. Structure of the δ-opioid receptor bound to naltrindole. Granier S; Manglik A; Kruse AC; Kobilka TS; Thian FS; Weis WI; Kobilka BK Nature; 2012 May; 485(7398):400-4. PubMed ID: 22596164 [TBL] [Abstract][Full Text] [Related]
5. 3D modeling, ligand binding and activation studies of the cloned mouse delta, mu; and kappa opioid receptors. Filizola M; Laakkonen L; Loew GH Protein Eng; 1999 Nov; 12(11):927-42. PubMed ID: 10585498 [TBL] [Abstract][Full Text] [Related]
6. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study. Bera I; Laskar A; Ghoshal N J Mol Model; 2011 May; 17(5):1207-21. PubMed ID: 20661609 [TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies. Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203 [TBL] [Abstract][Full Text] [Related]
9. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists. Larson DL; Jones RM; Hjorth SA; Schwartz TW; Portoghese PS J Med Chem; 2000 Apr; 43(8):1573-6. PubMed ID: 10780914 [TBL] [Abstract][Full Text] [Related]
10. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. Portoghese PS; Sultana M; Takemori AE J Med Chem; 1990 Jun; 33(6):1714-20. PubMed ID: 2160538 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975 [TBL] [Abstract][Full Text] [Related]
12. Delta opioid binding selectivity of 3-ether analogs of naltrindole. Coop A; Pinto J; Wang L; McCullough K; Rothman RB; Dersch C; Jacobson AE; Rice KC Bioorg Med Chem Lett; 1999 Dec; 9(24):3435-8. PubMed ID: 10617086 [TBL] [Abstract][Full Text] [Related]
13. delta-Opioid receptor: the third extracellular loop determines naltrindole selectivity. Li X; Varga EV; Stropova D; Zalewska T; Malatynska E; Knapp RJ; Roeske WR; Yamamura HI Eur J Pharmacol; 1996 Apr; 300(1-2):R1-2. PubMed ID: 8741185 [TBL] [Abstract][Full Text] [Related]
15. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor. Kong H; Raynor K; Yano H; Takeda J; Bell GI; Reisine T Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8042-6. PubMed ID: 8058754 [TBL] [Abstract][Full Text] [Related]
16. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors. Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951 [TBL] [Abstract][Full Text] [Related]
17. Characterization of [3H]naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: evidence for delta opioid receptor heterogeneity. Fang L; Knapp RJ; Horvath R; Matsunaga TO; Haaseth RC; Hruby VJ; Porreca F; Yamamura HI J Pharmacol Exp Ther; 1994 Feb; 268(2):836-46. PubMed ID: 8113996 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of a ligand targeting the μ and δ opioid receptors for drug delivery to lung cancer. Li G; Low PS Bioorg Med Chem Lett; 2017 May; 27(9):2074-2078. PubMed ID: 28291693 [TBL] [Abstract][Full Text] [Related]
19. Reporter affinity labels: an o-phthalaldehyde derivative of beta-naltrexamine as a fluorogenic ligand for opioid receptors. Le Bourdonnec B; El Kouhen R; Lunzer MM; Law PY; Loh HH; Portoghese PS J Med Chem; 2000 Jun; 43(13):2489-92. PubMed ID: 10891107 [No Abstract] [Full Text] [Related]
20. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Xie Z; Bhushan RG; Daniels DJ; Portoghese PS Mol Pharmacol; 2005 Oct; 68(4):1079-86. PubMed ID: 16006595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]